Abstract
BACKGROUND: Androgenetic alopecia is a widespread disorder that presents therapeutic challenges due to patients' inflated expectations, low treatment adherence associated with inconvenient topical application, and concerns regarding adverse effects. Therefore, exploring new non-invasive approaches to managing hair loss and stimulating hair growth has become particularly relevant.
AIM: To evaluate the efficacy and tolerability of the needle-free JetPeel hydro-dermabrasion technology combined with a serum containing DHQG (dihydroquercetin-glucoside), glycine, zinc chloride, EGCG (epigallocatechin-gallate-glucoside), acetyl tetrapeptide-3, and biochanin A (from red clover extract) in women with androgenetic alopecia in a real-world clinical setting.
METHODS: A prospective, uncontrolled, pragmatic study was conducted, blinded to the trichogram assessor. It enrolled 22 women with Ludwig stage I–III androgenetic alopecia. The patients received JetPeel procedures with serum once weekly for 5 weeks, along with daily home application of the serum. The analyzed trichoscopic parameters included the proportion of terminal/vellus hairs, single/double/triple follicular units, hair diameter. Subjective satisfaction and comfort were assessed using a 5-point Likert scale and a Visual Analogue Scale, respectively.
RESULTS: After 5 weeks, a statistically significant reduction in the proportion of single follicular units by 20% (p = 0.001) and an increase in the proportion of double units by 11.8% (p = 0.003) were observed. Median satisfaction was 4.5 points (86.4% of patients rated the outcome as 4 or 5). Comfort according to Visual Analogue Scale was 8.9 ± 1.2 out of 10. No serious adverse events were reported.
CONCLUSION: The JetPeel technology with complex serum demonstrates early positive trichoscopic changes, high subjective satisfaction, and a favorable safety profile, supporting its recommendation as an additional treatment option for androgenetic alopecia in women.